Discover the groundbreaking patent by Endo International Plc for a recombinant nucleic acid molecule encoding collagenase I and II, revolutionizing therapeutic administration methods.

Objective: The purpose of the present study was to demonstrate clinical equivalence between the application of collagenase ointment at 24- and 48-hour intervals in the healing of pressure ulcers.

Add 1 ml of collagenase type IV (1 mg/ml) per well or 60-mm petri dish and incubate at 37 °C for 8–10 min in 5% CO 2. The incubation time with collagenase varies from batch to batch.

which are vitamin A derivatives and work by upregulating the cells that are responsible for collagen production and inhibits the enzyme that breaks down collagen (collagenase). My favorite ...

The study was a head-to-head comparison of ExcharEx with collagenase Santyl ointment in the debridement of non-viable tissue ...

Laboratory of Parasitology, Faculty of Pharmacy, University of Alcalá, Alcalá de Henares, Ctra. Madrid-Barcelona km. 33.600, Madrid 28871, Spain ...

Last month, the company announced data from the head-to-head comparison analyses of its lead asset, EscharEx with collagenase Santyl ointment. The data demonstrated the superiority of EscharEx ...

CBL-514 is the first product to treat cellulite at the raised areas. Currently, there is no effective and safe cellulite ...

At the Swiss Biotech Day Conference, key opinion leaders discussed ways to reduce disparities caused by reduced regulatory ...

Oral presentations include additional comparative data between EscharEx® and SANTYL®, and new analyses show strong ...

Aging Health. 2012;8(5):471-477. Osteoporosis associated with chronic glucocorticoid therapy appears to be an important medical problem, which may often be underestimated. Glucocorticosteroids ...